The high school of Tropical Health and the pharmaceutical company GlaxoSmithKline sign a agreement of partnership in third world diseases.

Paul Nguewa, Francisco Errasti and José María Fiandor. PHOTO: Manuel Castells

The high school of Tropical Health of the University of Navarra and the pharmaceutical company GlaxoSmithKline have signed an agreement agreement of partnership to contribute to the finding of new treatments for three diseases of countries in development: leishmaniasis, Chagas disease and African trypanosomiasis.

The research center of the University of Navarra and the international business thus join forces in the fight against these neglected diseases. "Our high school has always been open to the implementation of partnership programs to improve health. We are delighted to be able to count GSK as one of our partners today. It is a cause for optimism for millions of sick people in the poorest parts of the world. It will also help to combat emerging diseases in developed countries," says Dr. Paul Nguewa, director of high school Tropical Health. In his opinion, "good health is fundamental to human well-being and sustainable economic and social development ".

GSK has a research and development center in Tres Cantos (Madrid) dedicated to finding new treatments for diseases in countries at development. "There are clear synergies and common goals between the two centers. This initial agreement lays the groundwork instructions for future collaborations and projects between the different research groups at each center. At GSK we are committed to finding new treatments for these diseases that affect millions of people in less developed countries. We are aware that this is a task that we cannot do alone. Therefore, agreements such as this one are fundamental to advance towards the ultimate goal of reaching the neediest patients", explains Dr. José María Fiandor, director of the research Unit of the Diseases of the Developing World Drug Discovery Center (DDW Center) of GlaxoSmithKline.

high school of Tropical Health of the University of Navarra

Promoted, like the CIMAthrough the Foundation for Applied Medical research , the University of Navarra's Tropical Health high school seeks to cure diseases that affect the poorest countries, especially women and children. These diseases are present in about 150 countries and affect more than 1,000 million people in Africa, Latin America and Asia, and therefore have a great impact partner-health. Because of their incidence on the population and because, in many cases, they aggravate their poverty status , high school focuses its efforts on three pathologies: brucellosis, leishmaniasis and Chagas disease. The center brings basic research closer to clinical application, at partnership with hospitals and university research centers in these countries development. Its goal is to find solutions for diagnosis, treatment, prevention and control of these diseases. Currently, there are several ways to collaborate with high school:

- Transferring a pension plan to Alpha Plus Gestora, at no cost and maintaining its tax advantages. Half of the commission of management will go to the various projects of high school Tropical Health.
- Donating directly to the Foundation for Applied Medical research , with the CIF G82198524 and the current account ES8400754732710600100166.
- Sending an SMS from a Vodafone phone with the word CIMA to 28052. The full amount of the message (1.2 euros) is donated to high school .

GSK

GlaxoSmithKline is a leading international pharmaceutical company in research and healthcare. The heart of the local company's research and development is located at Tres Cantos Medicine Development Campus, which has two centers at research: the Disease of Developing World Drug Discovery (DDW) Center and the Molecular Discovery Research. The DDW, created in 2001, is the first Spanish center of research dedicated to finding new treatments for malaria, tuberculosis and other diseases such as leishmaniasis, sleeping sickness and Chagas disease.

GSK has recently launched the Tres Cantos Open Lab program, whose goal consists of sharing knowledge, experience and resources with other public or private organizations committed to the finding of drugs for neglected tropical diseases.